Latest Conference Coverage

Primary results presented at ECTRIMS 2025 suggest that body-weight–adjusted high-dose of ocrelizumab did not further slow disease progression in patients with primary progressive multiple sclerosis.

The vice president of scientific engagement at the Alzheimer’s Association provided clinical insights on the most major considerations and precautions clinicians should have about diagnostic and commercially available tests for suspected Alzheimer disease. [WATCH TIME: 3 minutes]

A phase 2 study presented at ECTRIMS 2025 showed that autologous adipose-derived mesenchymal stem cell therapy was safe and effective in patients with relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the associate professor of neurology at Yale School of Medicine talked about the 2024 diagnostic criteria, the preclinical phase of the disease, and progressive MS. [WATCH TIME: 3 minutes]

The executive director of The Sumaira Foundation (TSF) talked about TSF's research update and award ceremony held during ECTRIMS 2025. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ECTRIMS Congress.

A global panel of experts revised NMOSD diagnostic criteria and updated disease classifications, distinguishing aquaporin-4 antibody–positive disease from related conditions such as MOGAD.

New research highlights the effectiveness of paramagnetic rim lesions as a key biomarker for diagnosing multiple sclerosis, enhancing diagnostic accuracy.

At ECTRIMS 2025, the professor of neurology at the University of Basel talked about the decades of progress in MS therapeutics and highlighted the need for comprehensive, early assessments for patients. [WATCH TIME: 4 minutes]

At ECTRIMS 2025, experts discussed using AI-powered unstructured data processing to enhance understanding of drug efficacy, safety, and patient outcomes in multiple sclerosis. [WATCH TIME: 3 minutes]

MIL62 shows promising results in reducing relapse rates and disability progression in NMOSD, highlighting its potential as a groundbreaking treatment.

In a head-to-head phase 3 trial presented at ECTRIMS 2025, rituximab was noninferior to cladribine in preventing new or enlarging MRI lesions in relapsing-remitting multiple sclerosis.

In a late-breaking presentation at ECTRIMS 2025, findings showed that annual administration of rituximab was noninferior in efficacy to the 6-monthly treatment for relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the professor of neurology at Karolinska Institutet provided clinical insights on results from the phase 3 RIDOSE-MS trial of yearly rituximab in relapsing-remitting multiple sclerosis. [WATCH TIME: 5 minutes]

At ECTRIMS 2025, the interim chief executive officer at the Consortium of Multiple Sclerosis Centers discussed recent progress in multiple sclerosis for treatment and diagnosis. [WATCH TIME: 5 minutes]

Tiziana Life Sciences presents the design a phase 2a trial of nasal foralumab for treating nonactive secondary progressive MS at ECTRIMS 2025.

Tolebrutinib shows promise in improving quality of life for patients with nonrelapsing secondary progressive multiple sclerosis, according to recent trial findings.

Late-breaking results of the ORATORIO-HAND study presented at ECTRIMS 2025 suggest that ocrelizumab slowed both overall disability progression and loss of hand function in patients with primary progressive multiple sclerosis.

Ofatumumab shows promising efficacy in treating neuromyelitis optica spectrum disorder, significantly reducing relapse rates and improving patient outcomes.

Grace Therapeutics reveals promising results for GTx-104, an innovative IV treatment for aSAH, potentially transforming patient care in neurocritical settings.

The psychiatrist and founder of the Stuttering Treatment and Research Society discussed the historical persistence of stuttering, treatment gaps, and the nuances of managing psychiatric comorbidities. [WATCH TIME: 3 minutes]

At the 2025 STARS Research & Education Conference, Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted risk factors and care interventions for stuttering in children.

Speech-language pathologist Lisa LaSalle, PhD, professor at California State University, Monterey Bay, highlighted the role of interdisciplinary collaboration in the management of stuttering.

The founder of the Stuttering Treatment and Research Society (STARS) discussed the unmet needs in stuttering care, current management strategies, and the mission of STARS to drive education, collaboration, and treatment development.

The founder of the Stuttering Treatment and Research Society (STARS) detailed current therapeutic strategies for stuttering, the role of dopamine pathways, and the pressing need for FDA-approved options. [WATCH TIME: 4 minutes]

A groundbreaking study reveals the connection between GLP-1 hormones and brain inflammation in neuromyelitis optica spectrum disorder, suggesting new treatment avenues.

At the 2025 STARS Research & Education Conference, the assistant professor of neurobiology and behavior at Stony Brook University discussed the current understanding of stuttering. [WATCH TIME: 5 minutes]

New research highlights daridorexant's effectiveness in improving sleep for women experiencing insomnia during menopause, showcasing significant benefits in sleep quality.